DERMTECH INC (DMTK)
US24984K1051 - Common Stock
DMTK gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. Both the profitability and financial health of DMTK have multiple concerns. DMTK is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
DMTK had negative earnings in the past year.
DMTK had a negative operating cash flow in the past year.
In the past 5 years DMTK reported 4 times negative net income.
DMTK had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -82.74%, DMTK is not doing good in the industry: 72.35% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -176.44%, DMTK is doing worse than 68.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -82.74% | ||
| ROE | -176.44% | ||
| ROIC | N/A |
ROA(3y)-57.34%
ROA(5y)-43.66%
ROE(3y)-99.56%
ROE(5y)-68.72%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
DMTK's Gross Margin of 1.83% is fine compared to the rest of the industry. DMTK outperforms 73.89% of its industry peers.
DMTK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 1.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
DMTK does not have a ROIC to compare to the WACC, probably because it is not profitable.
DMTK has more shares outstanding than it did 1 year ago.
DMTK has more shares outstanding than it did 5 years ago.
The debt/assets ratio for DMTK has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -6.87, we must say that DMTK is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.87, DMTK is doing worse than 70.48% of the companies in the same industry.
DMTK has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
DMTK has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: DMTK outperforms 49.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.87 |
ROIC/WACCN/A
WACC9.18%
2.3 Liquidity
A Current Ratio of 4.59 indicates that DMTK has no problem at all paying its short term obligations.
DMTK has a Current ratio (4.59) which is comparable to the rest of the industry.
A Quick Ratio of 4.52 indicates that DMTK has no problem at all paying its short term obligations.
DMTK has a Quick ratio (4.52) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.59 | ||
| Quick Ratio | 4.52 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 19.28% over the past year.
Looking at the last year, DMTK shows a small growth in Revenue. The Revenue has grown by 5.47% in the last year.
DMTK shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.45% yearly.
EPS 1Y (TTM)19.28%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q39.78%
Revenue 1Y (TTM)5.47%
Revenue growth 3Y37.45%
Revenue growth 5YN/A
Revenue growth Q2Q31.24%
3.2 Future
The Earnings Per Share is expected to grow by 19.65% on average over the next years. This is quite good.
DMTK is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.21% yearly.
EPS Next Y34.19%
EPS Next 2Y19.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year16.58%
Revenue Next 2Y18.21%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for DMTK. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DMTK. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as DMTK's earnings are expected to grow with 19.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.65%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for DMTK!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
DERMTECH INC
NASDAQ:DMTK (5/3/2024, 7:00:01 PM)
After market: 0.65 +0.02 (+3.34%)0.629
0 (-0.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap21.78M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -82.74% | ||
| ROE | -176.44% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 1.83% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.59 | ||
| Quick Ratio | 4.52 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)19.28%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y34.19%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)5.47%
Revenue growth 3Y37.45%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y